Wells Fargo’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2
| Closed | -$8 | – | 7295 |
|
|
2024
Q3 | $8 | Sell |
2
-1
| -33% | -$6 | ﹤0.01% | 6712 |
|
|
2024
Q2 | $24 | Hold |
3
| – | – | ﹤0.01% | 6478 |
|
|
2024
Q1 | $260 | Hold |
3
| – | – | ﹤0.01% | 6439 |
|
|
2023
Q4 | $516 | Sell |
3
-5
| -63% | -$2.46K | ﹤0.01% | 6376 |
|
|
2023
Q3 | $5.69K | Hold |
8
| – | – | ﹤0.01% | 5935 |
|
|
2023
Q2 | $36.9K | Hold |
8
| – | – | ﹤0.01% | 5547 |
|
|
2023
Q1 | $21.2K | Hold |
8
| – | – | ﹤0.01% | 5613 |
|
|
2022
Q4 | $20.9K | Sell |
8
-2
| -20% | -$6.97K | ﹤0.01% | 5241 |
|
|
2022
Q3 | $40K | Hold |
10
| – | – | ﹤0.01% | 5056 |
|
|
2022
Q2 | $26K | Sell |
10
-6
| -38% | -$15.6K | ﹤0.01% | 5328 |
|
|
2022
Q1 | $51K | Sell |
16
-9
| -36% | -$38.7K | ﹤0.01% | 5648 |
|
|
2021
Q4 | $154K | Buy |
25
+15
| +150% | +$115K | ﹤0.01% | 5414 |
|
|
2021
Q3 | $92K | Buy |
+10
| New | +$85.9K | ﹤0.01% | 5422 |
|
|
2021
Q2 | – | Hold |
0
| – | -$2K | – | 7607 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 6654 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 6297 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 7053 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 6202 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6959 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6829 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6802 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6680 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6546 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6664 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6632 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6632 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6620 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6210 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6176 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6152 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 5994 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6055 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6010 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 5862 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 5847 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 5739 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 5621 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 5664 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 5927 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6462 |
|
|
2013
Q4 | – | Hold |
0
| – | -$2K | – | 5970 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 5464 |
|
Other funds holding SEEL
Wells Fargo's SEEL Position: Q4 2024 in Review
Wells Fargo sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 2 shares — an estimated $8 sold.
Wells Fargo first reported a position in SEEL in Q3 2021 and held it in 13 quarters. The position peaked at $154K in Q4 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.
- Wells Fargo reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Wells Fargo sold 2 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $8.
- Wells Fargo first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2021 and held it in 13 quarters.
- Wells Fargo's Seelos Therapeutics, Inc. Common Stock position peaked at $154K in Q4 2021.
- 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.